Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
Source: View publication →
In cisgender men and transgender women who have sex with men, long-acting injectable cabotegravir administered every 8 weeks was superior to daily oral TDF/FTC in preventing incident HIV infection, reducing the risk by 66%.
Key Findings
Study Design
Study Limitations
Clinical Significance
HPTN 083 established CAB-LA as a highly efficacious PrEP option that is superior to the previous gold standard of daily oral TDF/FTC in this high-risk population. By uncoupling HIV prevention from daily pill-taking, CAB-LA circumvents the primary driver of oral PrEP failure: poor adherence. It has subsequently become a pivotal tool in the global HIV prevention strategy, provided health systems can accommodate the required regular injection visits and sensitive diagnostic monitoring to mitigate the risk of INSTI resistance.
Historical Context
Prior to HPTN 083, oral TDF/FTC and TAF/FTC were the only FDA-approved PrEP modalities. While highly effective biologically, their real-world impact was blunted by significant adherence challenges, particularly in marginalized populations facing the highest HIV risk. The HPTN 083 trial was the first to demonstrate the efficacy of a long-acting injectable integrase inhibitor for PrEP, proving superiority over daily pills and leading to the FDA approval of Apretude in December 2021. This marked a transformative milestone in HIV prevention by offering a discreet, non-daily alternative.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of cabotegravir compared to TDF/FTC, and why might an injectable formulation of this specific class be advantageous for HIV pre-exposure prophylaxis (PrEP)?
Key Response
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that prevents viral DNA insertion into the host genome, whereas TDF/FTC are NRTIs that cause premature chain termination. Injectables bypass gastrointestinal absorption and daily adherence requirements, which is critical since PrEP efficacy is heavily dependent on strict compliance.
Before initiating a patient on long-acting injectable cabotegravir for PrEP, what baseline and ongoing laboratory monitoring is required, particularly regarding HIV testing modalities?
Key Response
Patients must have a confirmed negative HIV test before starting and prior to each injection. Because CAB-LA can suppress viral replication and delay antibody production, breakthrough infections can be difficult to detect, often requiring HIV RNA PCR testing rather than just antigen/antibody assays to rule out acute infection and prevent INSTI resistance.
In the HPTN 083 trial, incident HIV infections occurred in the cabotegravir arm despite on-time injections, and some developed INSTI resistance. How does the pharmacokinetic 'tail' of cabotegravir complicate the diagnosis and management of these breakthrough infections?
Key Response
The long pharmacokinetic tail means sub-therapeutic drug levels persist for months after cessation. If a patient acquires HIV during this tail, the virus is exposed to low-level drug pressure, selecting for INSTI resistance mutations (e.g., Q148R). This severely compromises first-line HIV treatment regimens, which rely heavily on integrase inhibitors like dolutegravir.
HPTN 083 demonstrated superiority of cabotegravir over TDF/FTC. How should we interpret this superiority—is it driven by a higher intrinsic biological efficacy of the drug, or by behavioral factors, and how does this change our counseling?
Key Response
The superiority is almost entirely driven by adherence rather than intrinsic biological superiority. TDF/FTC is highly effective when taken daily, but adherence wanes over time. CAB-LA removes the daily pill burden, making it preferable for patients struggling with adherence, though strict compliance to the every-8-week clinic injection schedule must be emphasized.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
HPTN 083 utilized a double-blind, double-dummy design. What are the methodological strengths and limitations of this design in an HIV prevention trial, particularly concerning the estimation of real-world efficacy and drop-out rates?
Key Response
The double-dummy design controls for the placebo effect and behavioral risk compensation. However, requiring participants to take daily pills (one active, one placebo) AND receive regular injections creates an artificially high adherence burden that does not reflect real-world use of a single modality, potentially increasing drop-out rates or misrepresenting true adherence advantages.
The trial was stopped early by the DSMB due to demonstrated superiority. As a critical reviewer, what are the potential threats to validity when a prevention trial is stopped early, particularly regarding long-term safety and the evaluation of the 'tail' phase?
Key Response
Early stopping due to efficacy can truncate long-term safety data collection and exaggerate treatment effects. In this study, early termination meant fewer data points on the long-term consequences of the pharmacokinetic tail, the true incidence of INSTI resistance upon discontinuation, and whether the observed superiority is maintained over years of injection adherence fatigue.
Based on the superiority demonstrated in HPTN 083, how should current guidelines position CAB-LA relative to oral TDF/FTC, and what system-level barriers must be addressed in the recommendation?
Key Response
Current CDC guidelines give CAB-LA a Grade A recommendation for PrEP. The committee must position it as a highly effective alternative, particularly for those with oral adherence challenges, while addressing implementation barriers: high drug costs, the clinical infrastructure required for deep gluteal injections every 2 months, and the need for high-sensitivity RNA testing protocols to monitor for breakthrough infections.
Clinical Landscape
Noteworthy Related Trials
iPrEx Trial
Tested
Daily oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF)
Population
HIV-negative men and transgender women who have sex with men
Comparator
Placebo
Endpoint
Incident HIV infection
HPTN 084 Trial
Tested
Long-acting injectable cabotegravir every 8 weeks
Population
HIV-negative cisgender women at high risk of HIV
Comparator
Daily oral FTC/TDF
Endpoint
Incident HIV infection
DISCOVER Trial
Tested
Daily oral emtricitabine and tenofovir alafenamide (F/TAF)
Population
HIV-negative men and transgender women who have sex with men
Comparator
Daily oral FTC/TDF
Endpoint
Incident HIV infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis